Category: Industry Insights

Drugs for Cancer, Arthritis, and HIV on Medicare’s List for 2028 Price Cuts Summary The federal government has announced the next 15 medicines for which it will seek price reductions

Summary The Trump administration has announced two new Medicare pilot programs, “Globe” and “Guard”, that aim to lower drug prices by tying rebates to prices paid in comparable countries. Tanabe

Biopharma Climbs Higher as 9 Drugmakers Ink ‘Pandering’ Drug Price Deals with Trump Summary Nine drugmakers have recently inked deals with President Trump to offer discounts on specific drugs in

Summary BioMarin Pharmaceutical has announced its acquisition of Amicus Therapeutics in an all-cash deal worth $4.8 billion. This deal is expected to close between April and June of next year

Summary: Insmed, a biotechnology company, experienced a significant drop in their stock price after announcing that their drug brensocatib failed a Phase 2b study for a chronic nasal condition. This

Eli Lilly’s Experimental Obesity Pill Shows Promise in Phase 3 Trial Summary Eli Lilly’s experimental obesity pill, orforglipron, has shown potential as a weight maintenance treatment in a Phase 3

Sanofi MS drug hits two setbacks Summary Sanofi’s experimental drug, tolebrutinib, has failed to meet its main goal in a late-stage trial for primary progressive multiple sclerosis (MS). The company

Sobi Snaps Up Gout Drug in $950M Deal for Startup Arthrosi Summary Swedish pharmaceutical company Sobi has acquired Arthrosi Therapeutics, a biotechnology startup developing a potential treatment for gout, in

Lilly’s Retatrutide Shows Promising Results in Phase 3 Obesity Study Summary: Lilly’s experimental obesity drug, Retatrutide, has shown impressive results in a Phase 3 study, with patients on the highest